Medicure Appoints Kerrie Hayes, Q1 Revenue Jumps 46% to $7.9M
Medicure shareholders voted 5.24 million shares (50.19% of outstanding) at the AGM, electing Kerrie Hayes to the board. Q1 net revenue rose 46% to $7.9M, led by $2.3M from ZYPITAMAG and $5.7M in pharmacy sales; R&D spending of $855k lifted adjusted EBITDA to $280k and cut net loss to $406k.
1. Annual General Meeting Results
Shareholders cast 5,237,796 votes, representing 50.19% of outstanding common shares at the annual general meeting and elected Kerrie Hayes to the board of directors.
2. Q1 2026 Financial Performance
Medicure reported net revenue of $7.9 million for the quarter ended March 31, up from $5.4 million a year earlier. Sales included $2.3 million from ZYPITAMAG and $5.7 million in pharmacy segment revenue. R&D investment totaled $855,000, lifting adjusted EBITDA to $280,000 and narrowing the net loss to $406,000, or $0.04 per share.